

**IN THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

Claims 1-34 (Canceled)

Claim 35 (Currently amended): A composition for generating an immune response to a human prostate tumor-associated antigen in a human subject, comprising:

a proliferation-incompetent cell engineered to express GM-CSF selected from LnCaP[[.]] and PC3, wherein said composition is capable of eliciting ~~effects~~ a humoral immune response to a prostate tumor-associated antigen with a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as detected by SDS-PAGE, wherein said humoral immune response is not detected in said human subject prior to administering said composition and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

Claim 36 (Previously Presented): The composition of Claim 35, wherein said proliferation-incompetent cell is an LnCaP cell.

Claim 37 (Previously Presented): The composition of Claim 35, wherein said proliferation-incompetent cell is a PC3 cell.

Claim 38 (Cancelled)

Claim 39 (Previously Presented): The composition of Claim 36, further comprising a proliferation-incompetent PC3 cell.

Claim 40 (Previously Presented): The composition of Claim 35, wherein said prostate tumor-associated antigen has a molecular weight of 250 kD.

Claims 41- 43 (Canceled)

Claim 44 (Previously Presented): The composition of Claim 39, wherein said LnCaP and PC3 cells are administered to said human subject in equal doses.

Claim 45 (Previously Presented): The composition of Claim 44, wherein said dose of LnCaP and PC3 cells is  $6 \times 10^7$  cells per cell type.

Claim 46 (Previously Presented): The composition of Claim 39, wherein said LnCaP and PC3 cells are administered subcutaneously.

Claim 47 (Previously Presented): The composition of Claim 39, wherein said LnCaP and PC3 cells express 200-300 ng GM-CSF per 10<sup>6</sup> cells.

Claim 48-59 (Cancelled)